United Kingdom (UK)
Recombinant monoclonal antibody to E-protein. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the B cell clone DV22.
Alternative Name(s) of Target: DENV EI/II; Dengue envelope protein domain I/II; E protein domain I/II; DENV EDI/II; EDI/II; DV 22; DV-22
Immunogen: Antibody DV22 was isolated from peripheral blood mononuclear cells collected from a patient diagnosed with dengue infection.
Specificity: This antibody recognises domain I and II of the envelope (E) protein of DENV4 only, shown by ELISA and Western blot.
Application Notes: DV22 has been used in cell-based assays and was shown to exhibit neutralisation and antibody-dependent enhancing activity using Vero and K562 cells (Beltramello et al, 2010). This antibody has also been characterised as EDI/II-specific by ELISA and Western blot. When generated as a LALA variant and supplied as a cocktail with two other anti-DENV mAbs, DV22 showed a complete lack of antibody-dependent enhancement (ADE) activity, whilst retaining the ability to neutralise DENV infection.
Antibody first published in:
Beltramello et al. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe. 2010 Sep 16;8(3):271-83. PMID:20833378
Note on publication:
Describes the characterisation of a large panel of anti-DENV mAbs isolated from DENV-infected patients.